| 4.64 0.44 (10.48%) | 06-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.63 | 1-year : | 6.3 |
| Resists | First : | 4.82 | Second : | 5.4 |
| Pivot price | 4.34  |
|||
| Supports | First : | 3.89 | Second : | 3.24 |
| MAs | MA(5) : | 4.26 |
MA(20) : | 4.54 |
| MA(100) : | 4.2 |
MA(250) : | 2.63 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 30 |
D(3) : | 21.4 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 5.8 | Low : | 0.89 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IRD ] has closed below upper band by 22.2%. Bollinger Bands are 16.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.67 - 4.69 | 4.69 - 4.71 |
| Low: | 4.16 - 4.17 | 4.17 - 4.2 |
| Close: | 4.6 - 4.64 | 4.64 - 4.67 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Wed, 03 Jun 2026
Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform (NASDAQ:IRD) - Seeking Alpha
Wed, 03 Jun 2026
IRD: Rapidly advancing gene therapies show early vision gains, with pivotal data expected soon - TradingView
Tue, 02 Jun 2026
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, - GlobeNewswire
Wed, 27 May 2026
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference - Yahoo! Finance Canada
Mon, 25 May 2026
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - Yahoo Finance
Wed, 20 May 2026
Foundation Fighting Blindness fund trims Opus Genetics (IRD) stake with 1.7M-share sale - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 3.448e+007 (%) |
| Held by Institutions | 11.2 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.298e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -666 % |
| Return on Assets (ttm) | -46.8 % |
| Return on Equity (ttm) | -7 % |
| Qtrly Rev. Growth | 1.198e+007 % |
| Gross Profit (p.s.) | -0.21 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | -1.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 26.59 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 3.11e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|